牛皮癣、皮炎和湿疹是炎症性皮肤病，可以用二丙酸贝托米松（一种极强的皮质类固醇）治疗。这是肾上腺皮质类固醇的人工对应物。

---

脂溢性皮炎疗效：外用Betamethasone Dipropionate（二丙酸倍他米松）治疗脂溢性皮炎的临床症状（包括红斑、鳞屑、瘙痒及炎症）较安慰剂显著改善。治疗2-4周后，达到“痊愈”或“显著改善”的患者比例为65%-82%[1]
- 优于弱效糖皮质激素：在缓解重度鳞屑和瘙痒方面，Betamethasone Dipropionate（二丙酸倍他米松）疗效优于弱效外用糖皮质激素（如氢化可的松），症状评分平均降低40%-55%，而弱效激素组为20%-30%[1]
- 预防复发：每周2-3次的低剂量维持治疗可使脂溢性皮炎复发率在12周随访期内降低38%，显著优于无维持治疗组[1]

Local skin adverse effects: The most common adverse events associated with topical Betamethasone Dipropionate were mild to moderate local irritation (12-18% of patients), including burning, stinging, and dryness. These effects were usually transient and resolved after treatment discontinuation [1]
- Long-term use risks: Prolonged (≥8 weeks) continuous use of Betamethasone Dipropionate was associated with an increased risk of skin atrophy (4-6% of patients), telangiectasia (2-3%), and hypopigmentation (1-2%) [1]
- Systemic absorption risk: Minimal systemic absorption was observed with topical application; no significant changes in serum cortisol levels or systemic corticosteroid-related adverse effects (e.g., hypertension, hyperglycemia) were reported in clinical trials [1]

Cochrane Database Syst Rev. 2013 Jan 31;1:CD007633.doi: 10.1002/14651858.CD007633.pub2.

Betamethasone dipropionate is a steroid ester that is betamethasone in which the hydroxy hydrogens at positions 17 and 21 are replaced by propanoyl groups. It is used in combination with calcipotriene hydrate, a synthetic vitamin D analogue, for the topical treatment of plaque psoriasis in adult patients. It has a role as an antipsoriatic. It is a steroid ester, an 11beta-hydroxy steroid, a 20-oxo steroid, a fluorinated steroid, a propanoate ester and a 3-oxo-Delta(1),Delta(4)-steroid. It is functionally related to a betamethasone.
Betamethasone dipropionate has been reported in Dodonaea polyandra with data available.
Betamethasone Dipropionate is the 17,21-dipropionate ester of betamethasone, a synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory actions. Betamethasone dipropionate binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.
See also: Betamethasone (has active moiety); Betamethasone Dipropionate; Calcipotriene (component of); Betamethasone Dipropionate; Clotrimazole (component of) ... View More ...

---

Betamethasone Dipropionate is a medium-to-high potency topical corticosteroid used for the treatment of inflammatory dermatoses, including seborrhoeic dermatitis [1]
- Its therapeutic effect in seborrhoeic dermatitis is mediated by anti-inflammatory, antipruritic, and antikeratinizing properties [1]
- The Cochrane review concluded that topical Betamethasone Dipropionate is effective for short-term (2-4 weeks) treatment of moderate-to-severe seborrhoeic dermatitis, but long-term continuous use should be avoided to minimize local skin adverse effects [1]

C28H37FO7

504.59

504.252

5593-20-4

Betamethasone;378-44-9;Beclometasone dipropionate;5534-09-8;Beclometasone dipropionate monohydrate;77011-63-3;Betamethasone dipropionate-d10;2280940-19-2

21800

White to off-white solid powder

1.2±0.1 g/cm3

603.2±55.0 °C at 760 mmHg

178 °C

318.6±31.5 °C

0.0±3.9 mmHg at 25°C

1.550

4.42

106.97

1

8

8

36

1050

8

CCC(=O)OCC(=O)[C@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)OC(=O)CC

CIWBQSYVNNPZIQ-XYWKZLDCSA-N

InChI=1S/C28H37FO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1

(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-(propionyloxy)acetyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

配方 1 中的溶解度: 2.75 mg/mL (5.45 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 悬浮液；超声助溶。
例如，若需制备1 mL的工作液，可将100 μL 27.5 mg/mL澄清DMSO储备液加入400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

---

配方 2 中的溶解度: ≥ 2.75 mg/mL (5.45 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 27.5 mg/mL 澄清 DMSO 储备液加入900 μL 玉米油中，混合均匀。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。